Immunotherapy of Glioblastoma: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Subjects: Immunology
Contributor:
Barbara Breznik

Glioblastoma is the most common brain malignant tumor in the adult population, and immuno-therapy is playing an increasingly central role in the treatment of many cancers. Nevertheless, the search for effective immunotherapeutic approaches for glioblastoma patients continues. The goal of immunotherapy is to promote tumor eradication, boost the patient’s innate and adaptive im-mune responses, and overcome tumor immune resistance. A range of new, promising immuno-therapeutic strategies has been applied for glioblastoma, including vaccines, oncolytic viruses, immune checkpoint inhibitors, and adoptive cell transfer. However, the main challenges of im-munotherapy for glioblastoma are the intracranial location and heterogeneity of the tumor as well as the unique, immunosuppressive tumor microenvironment.

  • glioblastoma
  • immunotherapy
  • tumor model
  • stem cell
  • organoid
  • heterogeneity
  • immunosuppression
  • microenvironment

1. Introduction: Glioblastoma and Its Heterogeneity

The most aggressive and also most common primary brain tumor in adults is glioblastoma (Glioblastoma WHO grade IV). Glioblastoma is poorly responsive to therapy, which includes maximal surgical removal that is followed by chemotherapy and radiation therapy and has one of the shortest survival rates amongst all cancers [1]. For example, tumor treating fields treatment together with chemotherapy improved median overall survival of glioblastoma patients from 16 to 20.9 months [2]. Despite novel modalities in treatment, which rely on the Stupp protocol from 2005, the 5-year survival rate of patients is less than 5% [3][4][5]. Glioblastoma has distinct histological characteristics, including a pleomorphic cell composition, increased mitotic and cellular activity, and significant angiogenesis and necrosis [6]. The poor response of glioblastoma to treatment and its poor prognosis are associated with diffused invasion patterns within the central nervous system (CNS) [7]. Furthermore, the blood-brain barrier (BBB) presents both a physical and biochemical barrier to the CNS for large molecules [8][9]. Lymphatic vessels have been found in the meninges of humans and mice [10][11][12], causing the notion of the CNS as an immune-privileged system to be reconsidered. Brain-resident macrophages, i.e., microglia, are also now broadly recognized as antigen-presenting cells of the CNS. Although the brain is an immunologically distinct site, the brain microenvironment is capable of generating robust immune responses and offers adequate opportunities for the implementation of brain tumor immunotherapy [13]. In addition, the BBB can be disrupted in brain tumor patients, which increases the infiltration of immune cells into the tumor area. However, most GBM patients have variable regions of disrupted BBB, meaning that tumor regions with disrupted BBB and tumor regions with intact BBB exist [14].

The successful treatment of glioblastoma remains one of the most difficult challenges in brain cancer therapy. This is due to (1) the small population of therapy-resistant glioblastoma stem cells (GSCs) [15][16][17][18] and (2) inter- and intra-tumor heterogeneity that consists of a variety of different subtypes of glioblastoma [19] and stromal cells in the tumor microenvironment (TME) [20][21]. Glioblastomas have been genetically categorized by The Cancer Genome Atlas into three subtypes: proneural, classical, and mesenchymal. Each of these subtypes is characterized by mutations causing platelet-derived growth factor receptor alpha activation, epidermal growth factor receptor (EGFR) activation, and neurofibromin 1 deletions, respectively. Glioblastoma subtypes differ in their prognostic value, with mesenchymal and proneural subtypes exhibiting the shortest and longest overall survival rates, respectively [19]. Moreover, the composition of the TME is linked to the molecular subtypes of glioblastoma. Mesenchymal tumors contain abundant gene expression signatures for macrophages, CD4+ T cells, and neutrophils [22]; this is also associated with a higher glioma grade [19]. An increase in macrophages and microglia cells occurs upon disease recurrence and is associated with shorter relapse time after therapy.

GSCs are largely responsible for glioblastoma recurrence and therapy resistance due to their DNA repair and multi-drug resistance mechanisms as well as their ability to evade the immune response [23][24]. GSCs are maintained in hypoxic and peri-arteriolar GSC niches [25][26] and are more abundant in more aggressive, high-grade tumors with worse prognoses [27][28]. The glioblastoma TME regulates and determines the cellular state and drives GSC plasticity [29], which leads to the therapeutic resistance of tumors [30].

The predominant immune cells in the brain are macrophages, more specifically, tissue-resident macrophages known as microglia [31]. In brain cancer or other brain inflammatory conditions, additional peripheral monocytes are recruited from bone marrow and are differentiated in the brain into macrophages that are phenotypically distinct from microglia [32][33]. Immune cells are recruited and phenotypically changed by glioblastoma cells; this supports tumor growth and an immunosuppressive TME [34] through the release of cytokines, extracellular vesicles, and connecting nanotubes [35]. Chemoattraction between cells is mediated by members of a large family of chemokines [36][37]. For example, in glioblastoma, the chemokine (C-C motif) ligand 5 (CCL5) and its receptor C-C chemokine receptor type 5 (CCR5) are involved in autocrine and paracrine cross-talk between glioblastoma cells and the TME, contributing to stromal and immune cell tumor infiltration and glioblastoma cell invasion[38][39]. The attraction between endothelial and glioblastoma cells in GSC niches is predominantly maintained by the binding of C-X-C motif chemokine 12 (CXCL12, also known as stromal cell-derived factor 1α (SDF-1α)) to the C-X-C chemokine receptor type 4 (CXCR4) in GSCs.

2. The Immunosuppressive Microenvironment of Glioblastoma

Multi-layered immunosuppression exists in glioblastoma, both at the systemic and local level [40]. Systemic immunosuppression in glioblastoma patients is, to a large extent, induced by standard treatment including radiotherapy, temozolomide, and corticosteroids, which weakens the adaptive and innate immune responses [41]. Moreover, defects in antitumor responses arise from defective T cell mobilization from the periphery due to T cell entrapment in the bone marrow, which is caused by the loss of the surface sphingosine-1-phosphate receptor 1 (S1P1) [42][43] that binds the lipid second messenger sphingosine-1-phosphate (S1P) [44]. The S1P-S1P1 axis plays a role in governing lymphocyte trafficking. Naïve T cell egress from bone marrow or secondary lymphoid organs cannot occur without functional S1P1 on the cell surface, as S1P1 is essential for lymphocyte recirculation [45].

The glioblastoma microenvironment is extremely immunosuppressive due to its low immunogenicity, the immunosuppressive properties of many cells (including cancer cells, cancer stem cells (CSCs), and tumor-infiltrating immunosuppressive immune cells, e.g., myeloid cells and T regulatory cells (Tregs)), and the lack of antigen-presenting potential and costimulatory antigens, leading to tumor resistance to immunotherapy.

Glioblastoma cells and GSCs employ several mechanisms to evade the immune response. These include their intrinsic resistance to the induction of cell death, modulation of tumor antigens and cell surface molecules (which are important for the recognition and destruction of immune effector and antigen-presenting cells), and secretion of extracellular vehicles, cytokines, and growth factors. For example, glioblastoma cells express the programmed cell death receptor 1 ligand (PD-L1) that inhibits the cytotoxicity of cytotoxic T cells and downregulates major histocompatibility complex (MHC) class I, resulting in deficient T cell cytotoxicity. Moreover, glioblastoma cells may increase the expression of natural killer (NK) cell inhibitory ligands and decrease the expression of NK cell-activating NK group 2 member D (NKG2D) ligands, leading to inhibited NK cell-mediated lysis [46].

Glioblastoma is immunologically a cold tumor with low NK and T cell infiltration compared to other solid tumors. In glioblastoma, T and NK cells become dysfunctional. T cells are senescent, tolerant, exhausted, and anergic due to the immunosuppressive glioblastoma TME [47]. NK cells are important as immune effectors of the first line of defense against tumor cells and have been shown to control metastasis by eliminating circulating cancer cells [48]. The proposed mechanisms for the functional inactivation of tumor-associated NK cells are the overexpression of Fas ligand, the loss of mRNA for granzyme B [49], and the decrease of CD16 and its associated zeta chain [50][51][52]. T and NK cell dysfunction is also caused by co-expression of multiple co-inhibitory receptors, including programmed cell death protein 1 (PD-1), T cell immunoglobulin and mucin-domain containing-3 (TIM3), lymphocyte activation gene 3 protein (LAG3), cytotoxic T lymphocyte-associated protein 4 (CTLA-4), and T cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) [53].

Glioblastoma immunosuppressive TME is driven by tumor-intrinsic factors and brain (host) tissue responses to tumor antigens, such as overexpression of the indoleamine 2,3-dioxygenase (IDO) enzyme [54][55] and oncogene transforming growth factor-beta (TGF-β), respectively. IDO is a tryptophan catabolic enzyme overexpressed in several tumor types that creates an immunosuppressive microenvironment via the suppression of cytotoxic (CD8+) T cell proliferation and effector function [56] and the promotion of Treg generation via an aryl hydrocarbon receptor-dependent mechanism [56]. Cytokines, such as IL-10 and TGF-β, within the glioblastoma TME cause microglia to lose MHC expression [57][58]. TGF-β reduces NK and CD8+ T cell activation through inhibiting NKG2D expression, which is responsible for inducing lysis of NKG2D ligand-bearing cells that express class I MHC-related proteins, MHC Class I Polypeptide-Related Sequence A (MICA) and B, and the UL16 binding protein (ULB) 1–4 protein family [59].

Glioblastoma cells in the TME hijack many different cells to support tumor growth through the recruitment and suppression of many cells of the innate and adaptive immune responses. For example, Tregs and myeloid-derived suppressive cells that inhibit the proliferation and activation of effector cells (i.e., T cells and NK cells) and antigen-presenting cells are recruited. Increased numbers of forkhead box P3 (FOXP3)+ Tregs were found in glioblastoma [60][61]; however, their correlation with patient survival was modest [62][63]; Microglia and tumor-infiltrating macrophages influence immunosuppression by secreting the cytokine IL-10, TGF-β, and extracellular vesicles [64][65]. These complex interactions open new therapeutic windows for glioblastoma treatment. Colony-stimulating factor 1 (CSF-1) is a potent chemoattractant that regulates the differentiation of monocytes into tumor-associated macrophages (TAMs), and its overexpression correlates with increased TAM infiltration and poor clinical outcomes [66]. Inhibition of the CSF-1 receptor (CSF-1R) enhanced sensitivity to irradiation by altering both the recruitment and the phenotype of myeloid-derived cells recruited to the irradiated glioblastoma [67]. TAMs also express high levels of PD-L1 . Moreover, hypoxic conditions in the glioblastoma TME, through increased hypoxia-inducible factor (HIF) transcription factors and vascular endothelial growth factor (VEGF), increase TAM tumor infiltration.

This entry is adapted from the peer-reviewed paper 10.3390/cells10020265

References

  1. Louis, D.N.; Perry, A.; Reifenberger, G.; von Deimling, A.; Figarella-Branger, D.; Cavenee, W.K.; Ohgaki, H.; Wiestler, O.D.; Kleihues, P.; Ellison, D.W. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. Acta Neuropathol. 2016, 131, 803–820, doi:10.1007/s00401-016-1545-1.
  2. Stupp, R.; Taillibert, S.; Kanner, A.; Read, W.; Steinberg, D.M.; Lhermitte, B.; Toms, S.; Idbaih, A.; Ahluwalia, M.S.; Fink, K.; et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma a randomized clinical trial. JAMA-J. Am. Med. Assoc. 2017, 318, 2306–2316, doi:10.1001/jama.2017.18718.
  3. Noch, E.K.; Ramakrishna, R.; Magge, R. Challenges in the Treatment of Glioblastoma: Multisystem Mechanisms of Therapeutic Resistance. World Neurosurg. 2018, 116, 505–517, doi:10.1016/j.wneu.2018.04.022.
  4. Thomas, A.A.; Brennan, C.W.; DeAngelis, L.M.; Omuro, A.M. Emerging therapies for glioblastoma. JAMA Neurol. 2014, 71, 1437–1444, doi:10.1001/jamaneurol.2014.1701.
  5. Stupp, R.; Mason, W.P.; Van Den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.B.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352, 987–996, doi:10.1056/NEJMoa043330.
  6. Louis, D.N.; Ohgaki, H.; Wiestler, O.D.; Cavenee, W.K.; Burger, P.C.; Jouvet, A.; Scheithauer, B.W.; Kleihues, P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114, 97–109, doi:10.1007/s00401-007-0243-4.
  7. Omuro, A.; DeAngelis, L.M. Glioblastoma and other malignant gliomas: A clinical review. JAMA-J. Am. Med. Assoc. 2013, 310, 1842–1850, doi:10.1001/jama.2013.280319.
  8. Theodorakis, P.E.; Müller, E.A.; Craster, R.V.; Matar, O.K. Physical insights into the blood-brain barrier translocation mechanisms. Phys. Biol. 2017, 14, 041001, doi:10.1088/1478-3975/aa708a.
  9. Fokas, E.; Steinbach, J.P.; Rödel, C. Biology of brain metastases and novel targeted therapies: Time to translate the research. Biochim. Biophys. Acta-Rev. Cancer 2013, 1835, 61–75, doi:10.1016/j.bbcan.2012.10.005.
  10. Herisson, F.; Frodermann, V.; Courties, G.; Rohde, D.; Sun, Y.; Vandoorne, K.; Wojtkiewicz, G.R.; Masson, G.S.; Vinegoni, C.; Kim, J.; et al. Direct vascular channels connect skull bone marrow and the brain surface enabling myeloid cell migration. Nat. Neurosci. 2018, 21, 1209–1217, doi:10.1038/s41593-018-0213-2.
  11. Louveau, A.; Smirnov, I.; Keyes, T.J.; Eccles, J.D.; Rouhani, S.J.; Peske, J.D.; Derecki, N.C.; Castle, D.; Mandell, J.W.; Lee, K.S.; et al. Structural and functional features of central nervous system lymphatic vessels. Nature 2015, 523, 337–341, doi:10.1038/nature14432.
  12. Aspelund, A.; Antila, S.; Proulx, S.T.; Karlsen, T.V.; Karaman, S.; Detmar, M.; Wiig, H.; Alitalo, K. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J. Exp. Med. 2015, 212, 991–999, doi:10.1084/jem.20142290.
  13. Medikonda, R.; Dunn, G.; Rahman, M.; Fecci, P.; Lim, M. A review of glioblastoma immunotherapy. J. Neurooncol. 2020, doi:10.1007/s11060-020-03448-1.
  14. Oberoi, R.K.; Parrish, K.E.; Sio, T.T.; Mittapalli, R.K.; Elmquist, W.F.; Sarkaria, J.N. Strategies to improve delivery of anticancer drugs across the blood–brain barrier to treat glioblastoma. Neuro. Oncol. 2016, 18, 27–36, doi:10.1093/neuonc/nov164.
  15. Lathia, J.D.; Mack, S.C.; Mulkearns-hubert, E.E.; Valentim, C.L.L.; Rich, J.N. Cancer stem cells in glioblastoma. Genes Dev. 2015, 1203–1217, doi:10.1101/gad.261982.115.tumors.
  16. Chen, J.; Li, Y.; Yu, T.S.; McKay, R.M.; Burns, D.K.; Kernie, S.G.; Parada, L.F. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012, 488, 522–526, doi:10.1038/nature11287.
  17. Galli, R.; Binda, E.; Orfanelli, U.; Cipelletti, B.; Gritti, A.; De Vitis, S.; Fiocco, R.; Foroni, C.; Dimeco, F.; Vescovi, A. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004, 64, 7011–7021, doi:10.1158/0008-5472.CAN-04-1364.
  18. Osuka, S.; Van Meir, E.G. Overcoming therapeutic resistance in glioblastoma: The way forward. J. Clin. Investig. 2017, 127, 415–426, doi:10.1172/JCI89587.
  19. Verhaak, R.G.W.; Hoadley, K.A.; Purdom, E.; Wang, V.; Qi, Y.; Wilkerson, M.D.; Miller, C.R.; Ding, L.; Golub, T.; Mesirov, J.P.; et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17, 98–110, doi:10.1016/j.ccr.2009.12.020.
  20. Broekman, M.L.; Maas, S.L.N.; Abels, E.R.; Mempel, T.R.; Krichevsky, A.M.; Breakefield, X.O. Multidimensional communication in the microenvirons of glioblastoma. Nat. Rev. Neurol. 2018, doi:10.1038/s41582-018-0025-8.
  21. Teng, J.; Da Hora, C.C.; Kantar, R.S.; Nakano, I.; Wakimoto, H.; Batchelor, T.T.; Antonio Chiocca, E.; Badr, C.E.; Tannous, B.A. Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models. Neuro. Oncol. 2017, 19, 820–832, doi:10.1093/neuonc/now253.
  22. Wang, Q.; Hu, B.; Hu, X.; Kim, H.; Squatrito, M.; Scarpace, L.; deCarvalho, A.C.; Lyu, S.; Li, P.; Li, Y.; et al. Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell 2017, 32, 42–56.e6, doi:10.1016/j.ccell.2017.06.003.
  23. Otvos, B.; Silver, D.J.; Mulkearns-Hubert, E.E.; Alvarado, A.G.; Turaga, S.M.; Sorensen, M.D.; Rayman, P.; Flavahan, W.A.; Hale, J.S.; Stoltz, K.; et al. Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion. Stem Cells 2016, doi:10.1002/stem.2393.
  24. Alvarado, A.G.; Thiagarajan, P.S.; Mulkearns-Hubert, E.E.; Silver, D.J.; Hale, J.S.; Alban, T.J.; Turaga, S.M.; Jarrar, A.; Reizes, O.; Longworth, M.S.; et al. Glioblastoma Cancer Stem Cells Evade Innate Immune Suppression of Self-Renewal through Reduced TLR4 Expression. Cell Stem Cell 2017, doi:10.1016/j.stem.2016.12.001.
  25. Hira, V.V.V.; Aderetti, D.A.; van Noorden, C.J.F. Glioma Stem Cell Niches in Human Glioblastoma Are Periarteriolar. J. Histochem. Cytochem. 2018, 66, 349–358, doi:10.1369/0022155417752676.
  26. Hira, V.V.V.; Breznik, B.; Vittori, M.; Loncq de Jong, A.; Mlakar, J.; Oostra, R.J.; Khurshed, M.; Molenaar, R.J.; Lah, T.; Van Noorden, C.J.F. Similarities Between Stem Cell Niches in Glioblastoma and Bone Marrow: Rays of Hope for Novel Treatment Strategies. J. Histochem. Cytochem. 2019, 68, doi:10.1369/0022155419878416.
  27. Ardebili, S.; Zajc, I.; Gole, B.; Campos, B.; Herold-Mende, C.; Drmota, S.; Lah, T. CD133/prominin1 is prognostic for GBM patient’s survival, but inversely correlated with cysteine cathepsins’ expression in glioblastoma derived spheroids. Radiol. Oncol. 2011, 45, 1–13, doi:10.2478/v10019-011-0015-6.
  28. Zeppernick, F.; Ahmadi, R.; Campos, B.; Dictus, C.; Helmke, B.M.; Becker, N.; Lichter, P.; Unterberg, A.; Radlwimmer, B.; Herold-Mende, C.C. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin. Cancer Res. 2008, 14, 123–129, doi:10.1158/1078-0432.CCR-07-0932.
  29. Dirkse, A.; Golebiewska, A.; Buder, T.; Nazarov, P.V.; Muller, A.; Poovathingal, S.; Brons, N.H.C.; Leite, S.; Sauvageot, N.; Sarkisjan, D.; et al. Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment. Nat. Commun. 2019, 10, 1–16, doi:10.1038/s41467-019-09853-z.
  30. Perus, L.J.M.; Walsh, L.A. Microenvironmental Heterogeneity in Brain Malignancies. Front. Immunol. 2019, 10, 2294.
  31. Ajami, B.; Bennett, J.L.; Krieger, C.; Tetzlaff, W.; Rossi, F.M.V. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat. Neurosci. 2007, 10, 1538–1543, doi:10.1038/nn2014.
  32. Lund, H.; Pieber, M.; Parsa, R.; Han, J.; Grommisch, D.; Ewing, E.; Kular, L.; Needhamsen, M.; Espinosa, A.; Nilsson, E.; et al. Competitive repopulation of an empty microglial niche yields functionally distinct subsets of microglia-like cells. Nat. Commun. 2018, 9, 1–13, doi:10.1038/s41467-018-07295-7.
  33. Mildner, A.; Schmidt, H.; Nitsche, M.; Merkler, D.; Hanisch, U.K.; Mack, M.; Heikenwalder, M.; Brück, W.; Priller, J.; Prinz, M. Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat. Neurosci. 2007, 10, 1544–1553, doi:10.1038/nn2015.
  34. Thorsson, V.; Gibbs, D.L.; Brown, S.D.; Wolf, D.; Bortone, D.S.; Ou Yang, T.H.; Porta-Pardo, E.; Gao, G.F.; Plaisier, C.L.; Eddy, J.A.; et al. The Immune Landscape of Cancer. Immunity 2018, 48, 812–830.e14, doi:10.1016/j.immuni.2018.03.023.
  35. Matias, D.; Balça-Silva, J.; da Graça, G.C.; Wanjiru, C.M.; Macharia, L.W.; Nascimento, C.P.; Roque, N.R.; Coelho-Aguiar, J.M.; Pereira, C.M.; Dos Santos, M.F.; et al. Microglia/astrocytes–glioblastoma crosstalk: Crucial molecular mechanisms and microenvironmental factors. Front. Cell. Neurosci. 2018, 12, 235, doi:10.3389/fncel.2018.00235.
  36. Breznik, B.; Motaln, H.; Turnšek, T.L. Proteases and cytokines as mediators of interactions between cancer and stromal cells in tumours. Biol. Chem. 2016, 398, 709–719, doi:10.1515/hsz-2016-0283.
  37. O’Hayre, M.; Salanga, C.L.; Handel, T.M.; Allen, S.J. Chemokines and cancer: Migration, intracellular signalling and intercellular communication in the microenvironment. Biochem. J. 2008, 409, 635–649, doi:10.1042/BJ20071493.
  38. Novak, M.; Koprivnikar Krajnc, M.; Hrastar, B.; Breznik, B.; Majc, B.; Mlinar, M.; Rotter, A.; Porčnik, A.; Mlakar, J.; Stare, K.; et al. CCR5-Mediated Signaling Is Involved in Invasion of Glioblastoma Cells in Its Microenvironment. Int. J. Mol. Sci. 2020, 21, 4199, doi:10.3390/ijms21124199.
  39. Kranjc, M.K.; Novak, M.; Pestell, R.G.; Lah, T.T. Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme. Radiol. Oncol. 2019, 53, 397–406, doi:10.2478/raon-2019-0057.
  40. Grabowski, M.M.; Sankey, E.W.; Ryan, K.J.; Chongsathidkiet, P.; Lorrey, S.J.; Wilkinson, D.S.; Fecci, P.E. Immune suppression in gliomas. J. Neurooncol. 2020, doi:10.1007/s11060-020-03483-y.
  41. Lim, M.; Xia, Y.; Bettegowda, C.; Weller, M. Current state of immunotherapy for glioblastoma. Nat. Rev. Clin. Oncol. 2018, 15, 422–442, doi:10.1038/s41571-018-0003-5.
  42. Chongsathidkiet, P.; Jackson, C.; Koyama, S.; Loebel, F.; Cui, X.; Farber, S.H.; Woroniecka, K.; Elsamadicy, A.A.; Dechant, C.A.; Kemeny, H.R.; et al. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat. Med. 2018, 24, 1459–1468, doi:10.1038/s41591-018-0135-2.
  43. Antunes, A.R.P.; Scheyltjens, I.; Duerinck, J.; Neyns, B.; Movahedi, K.; Van Ginderachter, J.A. Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies. Elife 2020, 9, doi:10.7554/eLife.52176.
  44. Garris, C.S.; Blaho, V.A.; Hla, T.; Han, M.H. Sphingosine-1-phosphate receptor 1 signalling in T cells: Trafficking and beyond. Immunology 2014, 142, 347–353, doi:10.1111/imm.12272.
  45. Matloubian, M.; Lo, C.G.; Cinamon, G.; Lesneski, M.J.; Xu, Y.; Brinkmann, V.; Allende, M.L.; Proia, R.L.; Cyster, J.G. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004, 427, 355–360, doi:10.1038/nature02284.
  46. Golán, I.; De La Fuente, L.R.; Costoya, J.A. NK cell-based glioblastoma immunotherapy. Cancers (Basel) 2018, 10, doi:10.3390/cancers10120522.
  47. Adhikaree, J.; Moreno-Vicente, J.; Kaur, A.P.; Jackson, A.M.; Patel, P.M. Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma. Cells 2020, 9, 263, doi:10.3390/cells9020263.
  48. Lo, H.C.; Xu, Z.; Kim, I.S.; Pingel, B.; Aguirre, S.; Kodali, S.; Liu, J.; Zhang, W.; Muscarella, A.M.; Hein, S.M.; et al. Resistance to natural killer cell immunosurveillance confers a selective advantage to polyclonal metastasis. Nat. Cancer 2020, 1, 709–722, doi:10.1038/s43018-020-0068-9.
  49. Mulder, W.M.C.; Bloemena, E.; Stukart, M.J.; Kummer, J.A.; Wagstaff, J.; Scheper, R.J. T cell receptor-ζ and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma. Gut 1997, 40, 113–119, doi:10.1136/gut.40.1.113.
  50. Nakagomi, H.; Petersson, M.; Magnusson, I.; Juhlin, C.; Matsuda, M.; Mellstedt, H.; Vivier, J.L.T.; Anderson, P.; Kiessling, R. Decreased Expression of the Signal-transducing ζ Chains in Tumor-infiltrating T-Cells and NK Cells of Patients with Colorectal Carcinoma. Cancer Res. 1993, 53, 5610–5612.
  51. Romee, R.; Foley, B.; Lenvik, T.; Wang, Y.; Zhang, B.; Ankarlo, D.; Luo, X.; Cooley, S.; Verneris, M.; Walcheck, B.; et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood 2013, 121, 3599–3608, doi:10.1182/blood-2012-04-425397.
  52. Pellegatta, S.; Eoli, M.; Frigerio, S.; Antozzi, C.; Bruzzone, M.G.; Cantini, G.; Nava, S.; Anghileri, E.; Cuppini, L.; Cuccarini, V.; et al. The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates. Oncoimmunology 2013, 2, doi:10.4161/onci.23401.
  53. Wherry, E.J.; Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 2015, 15, 486–499, doi:10.1038/nri3862.
  54. Zhou, W.; Ke, S.Q.; Huang, Z.; Flavahan, W.; Fang, X.; Paul, J.; Wu, L.; Sloan, A.E.; McLendon, R.E.; Li, X.; et al. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat. Cell Biol. 2015, 17, 170–182, doi:10.1038/ncb3090.
  55. Komohara, Y.; Jinushi, M.; Takeya, M. Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci. 2014, 105, 1–8, doi:10.1111/cas.12314.
  56. Sheridan, C. IDO inhibitors move center stage in immuno-oncology. Nat. Biotechnol. 2015, 33, 321–322, doi:10.1038/nbt0415-321.
  57. Razavi, S.M.; Lee, K.E.; Jin, B.E.; Aujla, P.S.; Gholamin, S.; Li, G. Immune Evasion Strategies of Glioblastoma. Front. Surg. 2016, 3, doi:10.3389/fsurg.2016.00011.
  58. Roy, L.-O.; Poirier, M.-B.; Fortin, D. Transforming growth factor-beta and its implication in the malignancy of gliomas. Target. Oncol. 2015, 10, 1–14, doi:10.1007/s11523-014-0308-y.
  59. Crane, C.A.; Han, S.J.; Barry, J.J.; Ahn, B.J.; Lanier, L.L.; Parsa, A.T. TGF-β downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro. Oncol. 2010, 12, 7–13, doi:10.1093/neuonc/nop009.
  60. Jacobs, J.F.M.; Idema, A.J.; Bol, K.F.; Grotenhuis, J.A.; de Vries, I.J.M.; Wesseling, P.; Adema, G.J. Prognostic significance and mechanism of Treg infiltration in human brain tumors. J. Neuroimmunol. 2010, 225, 195–199, doi:10.1016/j.jneuroim.2010.05.020.
  61. El Andaloussi, A.; Lesniak, M.S. CD4+CD25+FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J. Neurooncol. 2007, 83, 145–152, doi:10.1007/s11060-006-9314-y.
  62. Thomas, A.A.; Fisher, J.L.; Rahme, G.J.; Hampton, T.H.; Baron, U.; Olek, S.; Schwachula, T.; Rhodes, C.H.; Gui, J.; Tafe, L.J.; et al. Regulatory T cells are not a strong predictor of survival for patients with glioblastoma. Neuro. Oncol. 2015, 17, 801–809, doi:10.1093/neuonc/nou363.
  63. Yue, Q.; Zhang, X.; Ye, H.X.; Wang, Y.; Du, Z.G.; Yao, Y.; Mao, Y. The prognostic value of Foxp3+ tumor-infiltrating lymphocytes in patients with glioblastoma. J. Neurooncol. 2014, 116, 251–259, doi:10.1007/s11060-013-1314-0.
  64. Li, W.; Graeber, M.B. The molecular profile of microglia under the influence of glioma. Neuro. Oncol. 2012, 14, 958–978, doi:10.1093/neuonc/nos116.
  65. Van Der Vos, K.E.; Abels, E.R.; Zhang, X.; Lai, C.; Carrizosa, E.; Oakley, D.; Prabhakar, S.; Mardini, O.; Crommentuijn, M.H.W.; Skog, J.; et al. Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia/macrophages in the brain. Neuro. Oncol. 2016, 18, 58–69, doi:10.1093/neuonc/nov244.
  66. Pollard, J.W. Trophic macrophages in development and disease. Nat. Rev. Immunol. 2009, 9, 259–270, doi:10.1038/nri2528.
  67. Stafford, J.H.; Hirai, T.; Deng, L.; Chernikova, S.B.; Urata, K.; West, B.L.; Brown, J.M. Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization. Neuro. Oncol. 2016, 18, 797–806, doi:10.1093/neuonc/nov272. 00
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Video Production Service
Feedback